News Archive - Ultimovacs

Biostock article: “Ultimovacs begins clinical evaluation of novel TET-platform”

26 februari, 2021 “After presenting their 2020 Q4 report, Ultimovacs immediately turned their attention back to 2021 by announcing the […]

“2020 was a year of key clinical advancements for Ultimovacs. In particular, the company’s already extensive development program with top […]

“Ultimovacs starter fase 2-studie for pasienter med alvorlig eggstokkreft – rekrutterer norske pasienter Ultimovacs har i den siste tiden startet […]

Ultimovacs – Phase II data from 500+ patients over 2022/23

“Ultimovacs announced yesterday that it will be participating in a phase II study in collaboration with AstraZeneca, along with the […]

“Ultimovacs går nå i gang med en fase 2 studie som skal undersøke effekten av å legge kreftvaksinen UV1 til […]

“Christmas came a few days early for Ultimovacs as the company was able to announce the initiation of its fourth […]

The company ticker on Oslo Børs has now changed from ULTIMO to ULTI.

In referanse to the Stock Exchange announcement on 2 November 2020 (below) where an abstract of the publication was available. […]

“Ultimovacs is developing a universal cancer vaccine with the aim of inducing an immune response in cancer patients that is […]